These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28793067)

  • 1. Farmácia Popular Program: pharmaceutical market analysis of antihypertensive acting on the renin-angiotensin system medicines.
    Silva RMD; Chaves GC; Chaves LA; Campos MR; Luiza VL; Bertoldi AD; Ross-Degnan D; Emmerick ICM
    Cien Saude Colet; 2017 Aug; 22(8):2501-2512. PubMed ID: 28793067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brazilian generics market change after Farmácia Popular program.
    Bertoldi AD; Chaves LA; Ross-Degnan D; Luiza VL; Emmerick ICM; Silva RMD; Campos MR
    Rev Saude Publica; 2019; 53():94. PubMed ID: 31644724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
    Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
    Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective interrupted time series examining hypertension and diabetes medicines usage following changes in patient cost sharing in the 'Farmácia Popular' programme in Brazil.
    Emmerick ICM; Campos MR; Luiza VL; Chaves LA; Bertoldi AD; Ross-Degnan D
    BMJ Open; 2017 Nov; 7(11):e017308. PubMed ID: 29101135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension and diabetes treatment affordability and government expenditures following changes in patient cost sharing in the "Farmácia popular" program in Brazil: an interrupted time series study.
    Emmerick ICM; Campos MR; da Silva RM; Chaves LA; Bertoldi AD; Ross-Degnan D; Luiza VL
    BMC Public Health; 2020 Jan; 20(1):24. PubMed ID: 31914972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current therapy: losartan].
    Degaute JP; Sternon J
    Rev Med Brux; 1997 Oct; 18(5):335-8. PubMed ID: 9441330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research Letter: Antihypertensive Drugs Market in India: An Insight on Size, Trends, and Prescribing Preferences in the Private Health Sector, 2016-2018.
    Sahoo SK; Pathni AK; Krishna A; Moran AE; Cohn J; Bhatia S; Maheshwari N; Sharma B
    Glob Heart; 2021; 16(1):51. PubMed ID: 34381673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [spACE, the last frontier? Renin inhibition in hypertension].
    Villa L
    G Ital Nefrol; 2008; 25(3):274. PubMed ID: 18473295
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
    Keiding H; Hildebrandt P; Burke T; Carides GW
    Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
    Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
    Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to antihypertensive agents in Brazil: evaluation of the "health has no price" program.
    Araujo JL; Pereira MD; de Sá Del Fiol F; Barberato-Filho S
    Clin Ther; 2014 Aug; 36(8):1191-5. PubMed ID: 24986486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the Pharmacoeconomic Aspects in the Clinical Management of Hypertension.
    Degli Esposti L; Degli Esposti E
    High Blood Press Cardiovasc Prev; 2016 Jun; 23(2):151-4. PubMed ID: 27160719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M; Rodrigue ME; Agharazii M; Larivière R
    Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren and dual therapy in type 2 diabetes mellitus.
    Ingelfinger JR
    N Engl J Med; 2008 Jun; 358(23):2503-5. PubMed ID: 18525047
    [No Abstract]   [Full Text] [Related]  

  • 17. Applying a health system perspective to the evolving Farmácia Popular medicines access programme in Brazil.
    Luiza VL; Chaves LA; Campos MR; Bertoldi AD; Silva RM; Bigdeli M; Ross-Degnan D; Emmerick ICM
    BMJ Glob Health; 2017; 2(Suppl 3):e000547. PubMed ID: 29527335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin system blocking drugs.
    Robles NR; Cerezo I; Hernandez-Gallego R
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):14-33. PubMed ID: 24038019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.